Legal & General Group’s Outlook Therapeutics OTLK Stock Holding History

Legal & General Group’s Portfolio OTLK Stock Details OTLK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-1,600	Closed	-$1.95K	–	3503
2025 Q1	$1.95K	Hold	1,600	–	–	﹤0.01%	3356
2024 Q4	$3.02K	Hold	1,600	–	–	﹤0.01%	3368
2024 Q3	$8.54K	Buy	1,600 +771	+93%	+$5.64K	﹤0.01%	3299
2024 Q2	$6.12K	Hold	829	–	–	﹤0.01%	3362
2024 Q1	$9.9K	Sell	829 -1	-0.1%	-$8	﹤0.01%	3202
2023 Q4	$6.53K	Hold	830	–	–	﹤0.01%	3294
2023 Q3	$3.67K	Sell	830 -118	-12%	-$2.61K	﹤0.01%	3379
2023 Q2	$32.9K	Sell	948 -2	-0.2%	-$55	﹤0.01%	2942
2023 Q1	$20.7K	Buy	950 +331	+53%	+$7.41K	﹤0.01%	3059
2022 Q4	$13.4K	Hold	619	–	–	﹤0.01%	3221
2022 Q3	$15K	Hold	619	–	–	﹤0.01%	3268
2022 Q2	$13K	Hold	619	–	–	﹤0.01%	3337
2022 Q1	$22K	Buy	619 +156	+34%	+$4.87K	﹤0.01%	3215
2021 Q4	$13K	Hold	463	–	–	﹤0.01%	3408
2021 Q3	$20K	Hold	463	–	–	﹤0.01%	3277
2021 Q2	$23K	Buy	+463	New	+$21.5K	﹤0.01%	3245

Other funds holding OTLK

SSA

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SPIA

Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Legal & General Group's OTLK Position: Q2 2025 in Review

Legal & General Group sold out of Outlook Therapeutics (OTLK) in Q2 2025, closing a stake of 1,600 shares — an estimated $1.95K sold.

Legal & General Group first reported a position in OTLK in Q2 2021 and held it in 16 quarters. The position peaked at $32.9K in Q2 2023. 66 funds tracked by Wall St. Rank hold OTLK as of Q2 2025.

Legal & General Group reported no remaining Outlook Therapeutics position as of Q2 2025 after selling out during the quarter.
Legal & General Group sold 1,600 Outlook Therapeutics shares in Q2 2025, an estimated $1.95K.
Legal & General Group first reported a position in Outlook Therapeutics in Q2 2021 and held it in 16 quarters.
Legal & General Group's Outlook Therapeutics position peaked at $32.9K in Q2 2023.
66 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q2 2025.

Based on Legal & General Group's 13F filing for Q2 2025, filed 12 Aug 2025.